Insider Buying: Antares Pharma Director Purchases 5,000 Shares of Stock (ATRS)
Antares Pharma (NASDAQ:ATRS) Director Robert P. Roche, Jr. purchased 5,000 shares of the company’s stock on the open market in a transaction dated Wednesday, August 13th. The stock was purchased at an average price of $1.96 per share, with a total value of $9,800.00. Following the completion of the purchase, the director now directly owns 28,172 shares of the company’s stock, valued at approximately $55,217. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Shares of Antares Pharma (NASDAQ:ATRS) opened at 2.14 on Monday. Antares Pharma has a one year low of $1.87 and a one year high of $5.15. The stock has a 50-day moving average of $2.27 and a 200-day moving average of $3.24. The company’s market cap is $279.2 million.
Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Thursday, August 7th. The company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.07). The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.43 million. Analysts expect that Antares Pharma will post $-0.24 EPS for the current fiscal year.
Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.
Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.